Recro Pharma to resubmit application for non-opioid pain medicine

Recro Pharma Inc. said Tuesday it expects to resubmit its new drug application for its lead product candidate, a non-opioid pain medicine, by the end of this month. In May, the Food and Drug Administration rejected the Malvern specialty pharmaceutical company's application seeking approval to market intravenous meloxicam for the management of moderate-to-severe pain. In its response letter, the FDA said the data suggested that the analgesic effect of the the rapy did not meet the agency's expectations. In…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news